Edodekin alfa

BIOLOGICAL2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Malignant Solid NeoplasmRecurrent Head and Neck Squamous Cell CarcinomaUnresectable Head and Neck Squamous Cell CarcinomaUnresectable Malignant Solid Neoplasm

Phase 1

Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Active, not recruitingNCT01468896

National Cancer Institute (NCI)Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma

Start: 2011-10-26End: 2027-03-31Updated: 2026-07-29

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

Active, not recruitingNCT03030378

National Cancer Institute (NCI)Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm

Start: 2018-05-30End: 2026-12-01Target: 36Updated: 2026-07-31